Background <p>Mucosal melanomas (MM) arise from mucosal melanocytes at various anatomical sites. These tumors are rare, highly aggressive, and often associated with poor outcomes. Current treatments, including immune checkpoint inhibitors, show limited efficacy in advanced disease. Compared with cutaneous melanomas, there is a lack of data on the immunogenicity and interferon (IFN)- sensitivity of MM. In this study, we examined…
Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas
Journal for ImmunoTherapy of Cancer | | Monti, M., Picinoli, S., Bozzola, A., Ferrari, M., Bugatti, M., Pezzali, I., Carlomagno, M., Carta, G., Orlandi, M., Lora, G., Benerini Gatta, L., Missale, F., Ferrari, G., Baldazzi, V., Rezzola, S., Tabellini, G., Parolini, S., Manfredi, M., De Giorgis, V., Marengo, E., Turri-Zanoni, M., Nicolai, P., Consoli, F., Lombardi, D., Martini, P., Li, J., Griffith, O., Griffith, M., Rossato, M., Vermi, W.
Topics: skin-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer